Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Ascendis Pharma A/S granted 14,060 warrants to certain employees on July 14, 2026 under Appendix 1a to its Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of US $265.57 per share.
Subject to earlier vesting upon specified exit events and continued service, 25% of the warrants vest on the first anniversary of the grant date and the remaining 75% vest in equal monthly installments over 36 months thereafter. After this grant, warrants to subscribe for 1,539,503 additional shares remain available for future grants. The report is deemed incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.
Positive
- None.
Negative
- None.
Key Figures
Employee warrants granted: 14,060 warrants
Exercise price: US $265.57 per share
Initial vesting portion: 25%
+2 more
5 metrics
Employee warrants granted
14,060 warrants
Granted to certain employees on July 14, 2026
Exercise price
US $265.57 per share
Exercise price for each newly granted warrant
Initial vesting portion
25%
Vests on the one-year anniversary of the grant date
Remaining vesting period
75% over 36 months
Balance vests monthly starting one year after grant
Warrants remaining available
1,539,503 warrants
Available for future grant under Articles of Association after this grant
Key Terms
Form 6-K, Articles of Association, warrants, exercise price, +1 more
5 terms
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Articles of Association regulatory
"under the terms of Appendix 1a to the Company’s Articles of Association"
A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.
warrants financial
"granted an aggregate of 14,060 warrants to certain employees"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
exercise price financial
"has an exercise price equal to US $265.57 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the Warrants will vest on the one year anniversary of the date of grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What new employee warrants did Ascendis Pharma (ASND) approve?
Ascendis Pharma approved 14,060 employee warrants on July 14, 2026. Each warrant allows subscription for one ordinary share at an exercise price of US $265.57, granted under Appendix 1a to the company’s Articles of Association as part of equity-based compensation.
How many warrants did ASND grant and at what exercise price?
Ascendis Pharma (ASND) granted 14,060 warrants with an exercise price of US $265.57 per share. Each warrant gives the right to subscribe for one ordinary share, using the closing market price on the July 14, 2026 grant date as the exercise price.
What is the vesting schedule for Ascendis Pharma’s new warrants (ASND)?
For Ascendis Pharma (ASND), 25% of the warrants vest on the first anniversary of the July 14, 2026 grant. The remaining 75% vest in equal monthly installments over 36 months, subject to continued service and possible earlier vesting on certain exit events.
How many additional warrants remain available for future ASND grants?
After this grant, Ascendis Pharma (ASND) has 1,539,503 warrants remaining available for future grants. These warrants are authorized under the company’s Articles of Association and may be granted later by the board of directors as part of equity incentive programs.
How is this Ascendis Pharma (ASND) warrant grant treated under SEC registrations?
The warrant grant report is deemed incorporated by reference into Ascendis Pharma’s existing Form S-8 and Form F-3 registration statements. This means related disclosures form part of those registered offerings from the filing date, unless later reports supersede them.